RecruitingNCT06720844

Idiopathic Central Precocious Puberty and Associated Neurodevelopmental Syndromes and Pathologies: Evaluation of Frequency and Comparison of Diagnostic and Developmental Characteristics


Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

300 participants

Start Date

Mar 13, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Observational, retrosopective, single-centre, non-profit study focused on the frequency of Central Precocious Puberty idiopathic, or associated to Neurodevelopmental Syndromes and Pathologies, and comparison of diagnostic and developmental characteristics of patients.


Eligibility

Max Age: 18 Years

Inclusion Criteria5

  • Patients diagnosed with Central Precocious Puberty presenting an indication to undertake treatment with GnRH analogue: Appearance of secondary sexual characteristics (thelarche or gonadarche) before the age of 8 for females and 9 for males; Acceleration of the rate of statural growth and advancement of bone age one year older than the chronological age; LH peak > 5 IU/L on GnRH test and a longitudinal uterine diameter > 36 mm in females, with or without the appearance of endometrial rhyme;
  • Age at onset of entral Precocious Puberty between 2 and 8 years (females) or between 2 and 9 years (males);
  • Age at enrollment < 18 years;
  • Follow-up of at least 12 months;
  • Obtaining informed consent from parents/legal guardian of peduatric patients.

Exclusion Criteria3

  • Isolated telarche and/or pubarche;
  • Peripheral forms of precocious puberty;
  • Patients diagnosed with primary organic Central Precocious Puberty due to tumour- or non-tumour-causing hypothalamic lesions.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Bolgona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06720844